Design | Inclusion criteria | Intervention arm | Control arm | Outcomes assessed | Estimated enrolment | Status | |
NCT02606188 Modified HFNC oxygen in patients undergoing bronchoscopy (China) | Randomised trial | Bronchoscopy required; baseline SpO2 ≥90% | Modified high-flow nasal cannula oxygen therapy | Conventional nasal cannula oxygen therapy | Time of bronchoscopy; lower SpO2 during bronchoscopy | 136 subjects | Not open |
NCT02253706 Oxygen supplementation during bronchoscopy: high-flow versus low-flow oxygen (Israel) | Randomised trial | Scheduled bronchoscopy for diagnostic purpose | High-flow nasal oxygen therapy with 50 L·min−1 flow, and FiO2 of 0.35 | Low-flow nasal oxygen | Oxygen desaturation of 4%; SpO2 cumulative time below 88%; number of bradycardia and tachycardia episodes; changes in expired end-tidal CO2; time with SpO2 <88%; patient comfort during procedure | 100 subjects | Not open |
NCT01650974 High-flow nasal oxygen therapy in high-risk patients of hypoxia undergoing diagnostic bronchoscopy (South Korea) | Randomised trial | PaO2 <60 mmHg or SpO2 <90% in room air and SpO2 ≥95% or PaO2 ≥75 mmHg with low flow oxygen; need for a diagnostic bronchoscopy | High flow nasal oxygen therapy with a 40 L·min−1 flow, and a FiO2 of 0.4 | Conventional nasal oxygen therapy with nasal prongs, with FiO2 of approx. 0.4; sham comparator: high-flow device with low-flow settings, and FiO2 0.4 | Success rate of bronchoscopy; total duration of hypoxia; frequency of hypoxia; switch to oxygen therapy method; change in respiratory symptoms | 152 subjects | Recruiting |
HFNC: high-flow nasal cannula SpO2: pulse oxygen saturation; FiO2: inspiratory oxygen fraction; PaO2: arterial oxygen tension.